8:00 am – 8:45 am Minimally Invasive Treatments Changing and Saving Lives – Dr. Safet Lekperic
8:45 am – 9:35 am Future of PET – Dr. Eric Snitzer and Dr. Patrick Lahr
9:35 am – 10:00 am Clinical Decision Support Update – Dr. David Wolf
10:00 am – 10:10 am Break
10:10 am – 10:55 am Breast Cancer Detection in Men – Dr. Anna Chen
10:55 am – 11:30 am Using AI for Breast and Genetic Risk Assessment – Laura Fisher, MS, CGC
11:30 am – 12:30 pm Liquid Plasma Biopsy – Dr. Herbert Duvivier
Minimally Invasive Treatment Changing and Saving Lives
Attendees will learn about minimally invasive treatment options for common conditions such as venous insufficiency, uterine fibroids, benign prostatic hypertrophy, and osteoporotic vertebral compression fractures. Cost and time efficiencies of minimally invasive treatments and the benefits of keeping patients out of the hospital will be discussed.
Future of Pet
A broad discussion on the overall usage and impact of PET/CT over the past decade, including the technical advances of PET/CT scanners, with a focus on digital technology. Attendees will better understand the clinical use over the past few years, and learn about additional radiotracers expected to be available in the near future and hear about the indications, pharmacology, efficacy and imaging of the various newer PET radiotracers.
Clinical Decision Support Update
This session will refresh primary care providers and other specialty providers on the ensuing mandate to utilize clinical decision support for all Medicare patients beginning Jan 1, 2021 and learn about the elements required in clinical order to rendering imaging provider and potential for incentive under the quality payment program. There will be a brief demonstration of the clinical decision support tools for select clinical indications.
Male Breast Cancer
Dr. Anna Chen will discuss the differences between breast cancer in men vs. women. Attendees will become more familiar with current guidelines in diagnosis and treatment and genetic testing for men and the possible implications of targeted screening for at risk men.
Using AI for Breast and Genetic Risk Assessment
Attendees will learn how artificial intelligence can improve efficiency in determining a patient’s lifetime breast cancer risk assessment identify more candidates for genetic counseling and testing. Details of how using artificial intelligence will increase compliance with USPSTF recommendations for mammography screening, genetic counseling and testing and more will also be discussed.
Liquid Plasma Biopsy
Attendees will learn what a liquid biopsy is and how liquid biopsy is utilized in the treatment of lung cancer.